BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

NIH launches Accelerating Medicines Partnership for schizophreniaNIH has partnered with FDA, non-profits and biopharmas to launch the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) initiative...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Nov 8, 2019
Preclinical News

Nov. 7 Preclinical Quick Takes: NIH drafts policy requiring more data sharing; plus Unum, Mission-BioLegend, DCprime and more

NIH pitches policy for greater sharing of data NIH has published a draft of the NIH Policy for Data Management and Sharing to promote wider sharing of data and results generated from NIH-funded grant work...
BioCentury | Oct 1, 2019
Company News

Oct. 1 Company Quick Takes: NVS, Microsoft to use AI for drug R&D; plus AstraZeneca, Tmunity-CHOP and AGTC-Otonomy deals

Novartis, Microsoft partner on AI for drug R&D Novartis AG (NYSE:NVS; SIX:NOVN) is partnering with Microsoft Corp. (NASDAQ:MSFT) to use artificial intelligence for drug development, with an initial focus on personalized macular degeneration therapies, cell...
BioCentury | Sep 4, 2019
Company News

Sept. 4 Company Quick Takes: Boehringer licenses Lupin MEK inhibitor; plus BMS-BioMotiv, KemPharm-GPC, Lilly, Nektar and Intellipharmaceutics

BI licenses Lupin's MEK inhibitor Boehringer Ingelheim (Ingelheim, Germany) licensed development and commercialization rights to MEK inhibitor LNP3794 from Lupin Ltd. (NSE:LUPIN; BSE:500257), which the pharma plans to test in combination with its KRAS inhibitors...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
BioCentury | Sep 14, 2018
Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
BioCentury | Sep 10, 2018
Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
Items per page:
1 - 10 of 435